Objective: To examine iron metabolism during the second and third trimesters in African American women with highrisk pregnancies.
A frican American women are more likely to have high-risk pregnancies than women in other racial/ethnic groups (Centers for Disease Control and Prevention, 2013) . This disparity may be due in part to greater rates of known risk factors, including preexisting conditions such as obesity (Ogden, Carroll, & Flegal, 2014) , hypertension (Go et al., 2013) , type 2 diabetes (Chow, Foster, Gonzalez, & McIver, 2012) , and adverse pregnancy-related conditions such as gestational diabetes mellitus and gestational hypertension (Ferrara, 2007) . Such disorders have also been reported to negatively influence iron metabolism in pregnant women of all racial/ethnic groups (Dao, Sen, Iyer, Klebenov, & Meydani, 2013; Garcia-Valdes et al., 2015; Phillips et al., 2014) . Several research teams have linked obesity (Dao et al., 2013; Garcia-Valdes et al., 2015; Jones et al., 2016) and gestational diabetes mellitus (Phillips et al., 2014) , conditions that would classify a pregnancy as high-risk, with iron deficiency (ID) and impaired iron metabolism in pregnancy.
ID during pregnancy, defined as a measurable decrease in circulating and body iron stores (Suominen, Punnonen, Rajamä ki, & Irjala, 1998) , is associated with a multitude of well-documented negative maternal and fetal health events that include greater risk for maternal and infant morbidity (Allen, 2000) , preterm birth (Siega-Riz et al., 2006) , and transient and irreversible neurocognitive defects in infants (Beard, MurrayKolb, Haas, & Lawrence, 2007) . All pregnant women are at risk for ID because a substantial increase in iron is required to support the expansion of the woman's blood volume and the growth of the placenta and fetus (McArdle, Lang, Hayes, & Gambling, 2011) . To fulfill this elevated iron demand, pregnant women are advised to increase their dietary iron intake from 16 to 27 mg daily (Institute of Medicine, Food and Nutrition Board, 2001) . Further, women's bodies adapt to changing iron needs via compensatory mechanisms that allow for greater dietary iron absorption and enhanced placental iron uptake and flux to the developing fetus (Bothwell, 2000; Rehu et al., 2010) . Recent estimates suggest that approximately 30% to 40% of pregnant women in the United States are classified with ID during the third trimester of pregnancy, and racial/ethnic minorities, specifically African American women, are at even greater risk than their non-Hispanic White counterparts (Mei et al., 2011) .
Regulation of systemic iron metabolism does not differ during gestation and is maintained by the hepatic-derived peptide hormone hepcidin (Ganz & Nemeth, 2012) . Hepcidin promotes degradation of the body's only known iron exporter, ferroportin-1 (Fpn). Degradation of Fpn reduces the transportation of iron into circulation from the diet and body storage sites (Ganz & Nemeth, 2012; Goodnough, Nemeth, & Ganz, 2010 ; see Figure 1 ). In the nonpregnant and pregnant states, hepcidin is simultaneously regulated by body iron stores, erythropoiesis, and systemic inflammation (Darshan & Anderson, 2009; see Figure 1 ). In the presence of systemic inflammation, hepcidin production and secretion from the liver is enhanced, which results in diminished Fpn expression and reduced iron export into circulation from stores and diet, or, in other words, iron restriction (Goodnough et al., 2010; see Figure 1 ).
In women who experience uncomplicated pregnancies, serum hepcidin levels have been reported to be very low or undetectable in the third trimester (Rehu et al., 2010; van Santen et al., 2011; Young et al., 2010) . It is believed that suppression of hepcidin is a compensatory mechanism that allows for enhanced dietary iron absorption and efflux of iron from a woman's body storage sites in pregnancy (Rehu et al., 2010) .
However, in conditions with underlying systemic inflammation, the flow of iron from the diet and body iron stores may be restricted because of elevated hepcidin (Dao et al., 2013) . In fact, investigators in one study showed that elevated hepcidin in women during the third trimester was associated with reduced dietary iron absorption (Young et al., 2010) . Thus, when coupled with a high demand for iron, such a state could exacerbate ID, given that iron from food and supplements may be less readily absorbed because of elevated hepcidin and suppressed Fpn. Therefore, the provision of additional oral iron may not resolve ID or improve iron status in pregnant women with inflammation-driven, hepcidin-mediated iron restriction.
Women with high-risk pregnancies may be a subset of pregnant women who are particularly vulnerable to adverse changes to iron metabolism and ID due to inflammation stemming from conditions of high-risk pregnancy (e.g., obesity, gestational diabetes, preexisting type 2 diabetes). Our goal in this small pilot study was to explore systemic iron metabolism, including hepcidin and systemic inflammation, in African American women during the second and third trimesters of high-risk pregnancies.
Methods

Design and Recruitment
Women who sought care at an urban maternalfetal medicine clinic affiliated with the University of Illinois Hospital and Health Sciences System were recruited for the pilot study. Eligibility criteria included singleton high-risk pregnancy, African American race, at least 15 years of age, born in the United States, living in the greater Chicago area, and able to read and write English. Exclusion criteria included major fetal anomaly, autoimmune disease (e.g., HIV, type 1 diabetes, rheumatoid arthritis, lupus, and Graves' disease), receipt of steroid treatments (including inhalers for asthma), sickle cell disease, or placement of a cervical cerclage. An obstetrician classified women as having high-risk pregnancies on the basis of their risk for prematurity or other pregnancy-related complications. At our maternal-fetal medicine clinic, high-risk was defined as previous preterm birth; current preterm birth; younger (<18 years old) or older age (>35 years old); pregnancyrelated conditions, including gestational diabetes mellitus and preeclampsia; and underlying health conditions, including preexisting hypertension and obesity.
Potential research participants at greater than 19 weeks gestation were approached by the research team (i.e., nursing students and student research assistants) in the maternal-fetal medicine clinic and provided with a description of the research study. Those who expressed interest in the study were invited to attend assessment visits in the second and third trimesters of their pregnancies. Informed written consent was obtained at the first visit by research staff. All study procedures were approved by the University of Illinois at Chicago Institutional Review Board.
Data Collection
Registered nurses from the University of Illinois at Chicago Clinical Research Center drew blood from participants' antecubital veins; fasting was not required before the blood draw. At the first visit (second trimester), pregnant women completed a demographic and health questionnaire to give information pertaining to relationship status, education level, smoking behavior, reproductive history, and past and current health status. The women also completed the Block Brief Food Frequency Questionnaire (FFQ) to report dietary intake and supplement use over the previous 3 months (Block et al., 1986) . Development and validation of this widely used dietary assessment questionnaire have been reported previously (Block, Hartman, & Naughton, 1990) . Participants with FFQ data that was deemed implausible (i.e., <500 calories or >5,000 calories daily) were excluded (n ¼ 4) from the dietaryrelated analyses. Prepregnancy body weight and height were obtained via self-report or abstracted from the University of Illinois at Chicago electronic health record by the research team to calculate prepregnancy body mass index (BMI).
Biochemical Analysis
Venous blood was processed for serum and stored at -80 C until analysis. Iron Metabolism in African American Women (Koperdanova & Cullis, 2015) .
In noninflammatory conditions, ferritin is a good marker of iron storage in the body. In inflammatory states, ferritin may be up-regulated because of inflammation and thus a poor indicator of body iron stores (Baynes, Bezwoda, Bothwell, Khan, & Mansoor, 1986 ). Interleukin-6 An inflammatory cytokine that has been shown to stimulate increased liver production of C-reactive protein (Heikkilä , Ebrahim, Rumley, Lowe, & Lawlor, 2007) and hepcidin (Nemeth et al., 2004 Choi, Im, & Pai (2000) . in this pilot study along with available, normal reference ranges in pregnancy. Serum ferritin, serum iron, transferrin, and transferrin saturation (TSAT) were assessed via immunoassay or spectrophotometry at a commercial lab. Circulating iron is delivered to cells via transferrin and its interaction with the cellular bound transferrin receptor (Beguin, 2003; Berlin, Meyer, RotmanPikielny, Natur, & Levy, 2011) . Soluble transferrin receptor (sTfR), the inflammatory markers, highsensitivity C-reactive protein (CRP), and highsensitivity interleukin-6 (IL-6) were analyzed in house via immunoassay. Serum hepcidin was assessed by competitive immunoassay (Ganz, Olbina, Girelli, Nemeth, & Westerman, 2008) . The sample size for several of the analytes varied by trimester because of the limited availability of serum (samples were being used for several other investigations) and hemolysis of a few samples intended for the iron-related markers. The number of available samples by trimester and number of women included in the longitudinal biomarker analysis are indicated in Table 2 .
Iron Status Classifications
We defined the prevalence of depleted iron stores, tissue ID, and ID in participants as follows. Depleted iron stores was defined as serum ferritin level less than 15 ng/ml (Centers for Disease Control and Prevention, 1998; Perry, Yip, & Zyrkowski, 1995) . Tissue ID was defined as sTfR concentration greater than 28.1 nmol/L (Duffy et al., 2010) , with the understanding that sTfR mostly reflects ID of erythroid tissue. Similar to Duffy et al., a ferritin level less than 15 ng/ml combined with a sTfR level greater than 28.1 nmol/L was used to define ID in the third trimester only.
Statistical Analyses
Data were managed using the Research Electronic Data Capture Web application (Vanderbilt University, Nashville, TN). Statistical analysis was performed using SAS version 9.4. Variable distributions were assessed for normality. Log transformations were applied to ferritin, hepcidin, CRP, IL-6, and TSAT because of their skewed distributions. Continuous variables are presented as means AE standard deviations or geometric means and 95% confidence intervals, and categoric variables are presented as frequencies and percentages. Paired t tests were used to compare changes in continuous variables between the second and third trimesters of pregnancy for women with available data. Spearman correlation coefficients were used to assess associations among maternal age, gravida, prepregnancy BMI, inflammatory markers, and the iron-related parameters at each time point. Statistical significance was set at a < .05.
Results
Participant demographic, health, and dietary characteristics are presented in Table 3 . In conditions in which the mother's hepcidin is elevated, the flow of iron from mother to fetus may be impaired.
Iron Metabolism in African American Women
Thirty-two women were recruited with a mean age of 28.3 AE 6.8 years, gravidity between 1 and 10, and mean prepregnancy BMI of 31.9 AE 10.7 kg/m 2 ; 47% of the women were classified as obese based on prepregnancy BMI. Because of missing responses for socioeconomic data, implausible FFQ data, and limited availability of serum in each trimester, the sample size available for analysis varies and is indicated as follows and in Tables 2  and 3 . A total of 77% (n ¼ 24 of 31) of participants received benefits from the Special Supplemental Nutrition Program for Women, Infants and Children, and 71% (n ¼ 22 of 31) received Illinois public aid. Thirteen percent of the participants (n ¼ 4 of 32) reported that they smoked in the second trimester. Nine percent (n ¼ 3 of 32) reported gestational diabetes mellitus, 6% (n ¼ 2 of 32) gestational hypertension, and 6% (n ¼ 2 of 32) preeclampsia in the second trimester. Mean dietary iron intake from food and supplements was 38.6 AE 26.9 mg daily as determined by the FFQ, and 57% of participants (n ¼ 16 of 28) met the recommended daily allowance for iron during pregnancy ($27 mg/day). Twenty-five percent of participants (n ¼ 8 of 32) reported hypertension, and 13% (n ¼ 4 of 32) reported type 2 diabetes mellitus as preexisting medical conditions. The biochemical data for the second and third trimesters are presented in Table 2 . The mean values presented are for the total available sample for each gestational time point. The longitudinal paired analysis is based on the total available sample or the smaller of the two analytic samples available in the second or third trimester. A significant decline in serum iron, ferritin, and TSAT and a significant increase in transferrin and sTfR were observed between the second and third trimesters in women with available longitudinal data. No significant change in hepcidin was found between the trimesters. However, a significant reduction in CRP and no change in IL-6 from mid-to late gestation were observed.
In the second trimester, 25% of participants (n ¼ 8 of 32) had depleted iron stores on the basis of a ferritin level cut point of less than 15 ng/ml; this increased in the third trimester to 53% (n ¼ 17 of 32). In the second (n ¼ 20 of 20) and third (n ¼ 29 or 29) trimesters, 100% of participants with available serum were characterized with tissue ID on the basis of sTfR levels greater than 28.1 nmol/ L. In the third trimester, 48% of participants (14 of 29; sTfR missing for 3 women) were classified with ID on the basis of serum ferritin level less than 15 ng/ml and sTfR level greater than 28.1 nmol/L.
The relationships among demographic, reproductive health, anthropometric, and biochemical parameters were examined in each trimester. In the second trimester, we observed a significant positive correlation between serum ferritin and hepcidin levels (r ¼ 0.65; p < .001) and a modest inverse correlation between hepcidin and sTfR levels (r ¼ -0.40; p ¼ .08), which suggests that hepcidin was being regulated to some degree by body iron stores. Prepregnancy BMI was significantly positively correlated with CRP (r ¼ 0.77, p < .001) and IL-6 (r ¼ 0.61, p ¼ .005) at midgestation, which suggests that greater adiposity was associated with increased inflammation at mid-gestation.
In the third trimester, the relationship between hepcidin and ferritin (r ¼ 0.30, p ¼ .09) and sTfR (r ¼ 0.30, p ¼ .09) weakened (r ¼ 0.30, p ¼ .09), 
Discussion
Our findings from this pilot study of iron metabolism in African American women with high-risk pregnancies suggest a greater prevalence of depleted iron stores in the third trimester. The rate of ID in our cohort was 48% in the third trimester, which is similar to the rate previously reported for African American adolescent girls in the third trimester (Iannotti et al., 2005) . In an analysis of the National Health and Nutrition Examination Survey conducted by Mei et al. (2011) , 39% of pregnant women from a nationally representative sample had ID during the third trimester on the basis of low serum ferritin concentrations. Thus, given the importance of iron sufficiency for maternal and fetal health, women with high-risk pregnancies may require close monitoring and screening for ID during the third trimester.
We observed statistically significant reductions of serum ferritin, iron, and TSAT and marked increases in transferrin and sTfR levels between the second and third trimesters, which suggests a decline in iron status during the later stages of pregnancy. This trend is comparable to results of previous reports of iron status during uncomplicated and high-risk pregnancy (Garcia-Valdes et al., 2015; Iannotti et al., 2005; Mei et al., 2011) . The observed decrease in iron stores parallels the significant rise in iron transfer to the fetus in the third trimester (Bothwell, 2000) .
We did not detect a significant decrease in hepcidin level between trimesters. Further, the level of hepcidin in the third trimester observed in our small cohort was somewhat higher than what was reported by researchers in other studies of healthy, pregnant, nonminority adult women. Rehu et al. (2010) reported geometric mean hepcidin concentrations of 12.4 ng/ml (95% confidence interval [10.5, 14.6]) in women when measured at labor and birth, and Young et al. (2010) reported a third trimester median hepcidin concentration of less than 5.0 ng/ml (range ¼ <5.0-207 ng/ml; the assay can only detect levels at or above 5 ng/ml). In a stable (i.e., not radioactive) iron isotope study (Young et al., 2010) , women with third trimester serum hepcidin levels greater than 5.0 ng/ml had lower dietary iron absorption than pregnant women with low or undetectable hepcidin concentrations. Thus, the third trimester hepcidin level observed in our small cohort suggests that iron bioavailability may have been restricted (i.e., reduced dietary iron absorption due to elevated hepcidin). However, additional studies designed to objectively assess iron absorption via stable iron isotopes, including a control group with uncomplicated pregnancies, are needed to confirm this hypothesis.
Nonetheless, this finding is of concern given that hepcidin suppression late in pregnancy is believed to be the compensatory mechanism that facilitates enhanced dietary iron absorption and iron efflux from a woman's stores to be presented to and transferred across the placenta to the fetus (Rehu et al., 2010) . Further, impaired iron bioavailability, particularly during the third trimester, can be detrimental to fetal neurocognitive development (Lozoff et al., 2006; Piñero, Li, Connor, & Beard, 2000) .
Hepcidin is simultaneously regulated by inflammation, body iron status, and erythropoiesis (Darshan & Anderson, 2009 ). Thus, hepcidin can be overexpressed because of underlying systemic inflammation even in the face of concurrent ID (Tussing-Humphreys, Nemeth, Fantuzzi, Freels, Guzman, et al., 2010) . This ID phenotype is considered a mixed ID in which the clinical hallmarks of frank ID (e.g., low serum ferritin and elevated sTfR levels) and the anemia of inflammation (e.g., elevated systemic inflammation, overexpressed hepcidin given the degree of ID) coexist (Yanoff et al., 2007) . In the third trimester, participants in our study had systemic inflammation greater than what has been reported in (Dao et al., 2013) . Further, mean dietary iron intake was greater than the recommended daily allowance of 27 mg, and more than 50% of participants met this intake threshold on the basis of data from the FFQ (Institute of Medicine, Food and Nutrition Board, 2001 ).
Thus, as suggested previously by our team and others, hepcidin-mediated changes to iron physiology, and not inadequate dietary iron, influence iron metabolism in persons with underlying inflammation (Cepeda-Lopez, Melse-Boonstra, Zimmerman, & Herter-Aeberli, 2015; CepedaLopez et al., 2011; Menzie et al., 2008; TussingHumphreys, Liang, Nemeth, Freels, & Braunschweig, 2009 ). It is suggested that the degree of hepcidin observed (i.e., mildly overexpressed) in persons with mixed ID may allow for iron mobilization from body iron stores but may lead to restricted dietary iron absorption (TussingHumphreys, Nemeth, Fantuzzi, Freels, Guzman, et al. 2010; . Therefore, simply providing additional iron via food or oral supplements may not correct ID or improve iron status in those with inflammation-induced, hepcidin-mediated, mixed ID. Presumably, interventions designed to lower inflammation could positively influence the inflammation-hepcidin-iron axis.
Although we did not observe a significant relationship between inflammation and hepcidin at any point during gestation, it is well established that inflammatory cytokines, specifically IL-6, upregulate hepatic hepcidin production via the Janus kinase/signal transducer and activator of transcription-3 (i.e., JAK/STAT3) pathway (Nemeth et al., 2003 (Nemeth et al., , 2004 . In a study of pregnant obese and lean adolescents, Cao et al. (2015) reported no association between IL-6 and hepcidin at midgestation. In another study, inflammation was positively correlated with hepcidin, although the investigators cautioned readers not to overstate this finding given that ferritin, known to be similarly influenced by inflammation, decreased substantially during gestation and was only weakly correlated with inflammatory markers (Garcia-Valdes et al., 2015) . Together these findings provide tentative evidence that other hepcidin-regulating signals, including body iron stores and erythropoiesis, may predominate in regulating hepcidin in pregnancy. This would account for why we observed only slightly overexpressed hepcidin in our cohort of women.
Strengths and Limitations
Our study had several strengths, which include the focus on a largely understudied population of women with elevated risk for high-risk pregnancies and ID. We also used multiple markers to characterize iron status and concurrently examined systemic inflammation, hepcidin, and dietary iron intake, all of which contribute substantially to iron metabolism in pregnant women. However, we acknowledge that this study is not without limitations. First, the cohort was a small convenience sample of pregnant African American women residing in Chicago. Because of the small sample size, our findings should be interpreted with caution. We were also not able to stratify the various high-risk conditions, prepregnancy BMI, or current smoking status because of the small sample size. Researchers recently suggested that a woman's hepcidin expression and iron metabolism can be affected differentially by prepregnancy BMI (Dao et al., 2013; Garcia-Valdes et al., 2015; Jones et al., 2016) , gestational diabetes (Phillips et al., 2014) , and smoking status (Chełchowska, Ambroszkiewicz, Jabło nska-Głąb, Maciejewski, & Ołtarzewski, 2016) .
Also, the findings may not be generalizable to African American women living in other areas of the United States or to women of other races/ ethnicities classified with high-risk pregnancies. Further, we did not have a healthy pregnant cohort for comparison. Prepregnancy body weight was typically obtained via self-report, which may have resulted in misclassification of prepregnancy BMI. However, classifying prepregnancy BMI on the basis of self-reported weight is not uncommon in studies of pregnant women (Cao et al., 2015; Holland, Moore Simas, Doyle Curiale, Liao, & Waring, 2013) . Many women in our study did not seek care at our institution before pregnancy, so often objectively measured weight could not be obtained from the electronic health record. The self-report nature of the surveys, including the FFQ, is not optimal. Self-reported data are subject to recall bias and socially desirable responses. Further, underreporting of food intake is common, particularly among obese individuals (Muhlheim, Allison, Heshka, & Heymsfield, 1998) . Finally, we did not
The provision of additional iron via food or oral supplements may not correct iron deficiency in pregnant women with inflammation-driven, hepcidin-mediated iron restriction.
assess participants for erythropoiesis because of insufficient serum available for analysis. Erythropoiesis is known to influence iron metabolism and specifically hepcidin production (Nemeth & Ganz, 2009) .
Clinical Considerations
Hepcidin is the master regulator of systemic iron metabolism (Ganz & Nemeth, 2012) . Overexpressed hepcidin may impair a woman's dietary iron absorption and thus exacerbate ID and reduce the amount of iron presented to the placenta and ultimately transferred to the fetus (Koenig, Tussing-Humphreys, Day, Cadwell, & Nemeth, 2014) . A mixed ID phenotype (Yanoff et al., 2007) triggered by inflammation-induced, hepcidin-mediated iron restriction is vastly different than frank ID, which is largely precipitated by inadequate dietary iron intake. Nurses and clinicians alike must consider hepcidinmediated iron restriction as a possible cause for ID in some cases in which women have increased inflammation because of underlying medical conditions, including those associated with highrisk pregnancies. However, the use of hepcidin in routine clinical care remains limited, although continuing analytic advances may soon allow for this biomarker to occupy a place in clinical practice (Miseta et al., 2015) . In the future, hepcidin may be an important clinical biomarker used to determine adverse changes to iron metabolism in pregnancy and identify those for whom iron supplementation would be most advantageous (i.e., women with low hepcidin concentrations). Further, researchers suggest that hepcidin level declines ahead of other iron status indicators (Rehu et al., 2010) . Thus, hepcidin may help to more quickly identify women who are in need of iron supplementation during pregnancy (Rehu et al., 2010) .
For now, in pregnant women with suspected hepcidin-mediated iron restriction or a mixed ID (i.e., those who are not responding to oral iron supplementation), examining inflammatory markers including CRP and erythrocyte sedimentation rate in conjunction with iron-related parameters including hemoglobin, ferritin, and sTfR may help to distinguish the cause of ID in pregnancy. Our group is focused on testing dietary approaches that have the potential to safely modulate systemic inflammation and hepcidin in an effort to improve iron bioavailability in high-risk pregnancy. Finally, it remains to be determined if overexpressed hepcidin has pathologic effects on maternal, fetal, and long-term offspring health outcomes, which makes this a very ripe area for clinical investigation.
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